Quick Answer
Inhibikase Therapeutics, Inc. reported Research And Development Expense of $29.79 million for the year ending 2025.
- Inhibikase Therapeutics, Inc. showed an increase of +73.1% in Research And Development Expense from 2024 to 2025.
- This data is from Inhibikase Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Inhibikase Therapeutics, Inc.'s Research And Development Expense has grown by 3,233.3%.
- Historical annual values: Fiscal year 2025: $29.79 million | Fiscal year 2024: $17.21 million | Fiscal year 2023: $13.62 million | Fiscal year 2022: $12.03 million | Fiscal year 2021: $11.36 million | Fiscal year 2020: $893.8 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: